Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study
Emmanuel S. Antonarakis·Charles J. Ryan·Victoria Catharine·Benedito A. Carneiro·Andre Luiz De Souza·David James VanderWeele·Parminder Singh·Alan H. Bryce·W. Kevin. Kelly·Gautam Jha·Brian Lewis·P. Barata·A. Oliver. Sartor·Walter M. Stadler·J. Proudfoot·Elai Davicioni·Mallika Dhawan·Alicia K. Morgans·Qing Cao
Cabazitaxel and carboplatin followed by abiraterone, together with ADT, was feasible, safe, and efficacious in patients with high-volume mCSPC, and warrants further study in larger randomized trials.